Boosting cytotoxicity of adoptive allogeneic NK cell therapy with an oncolytic adenovirus encoding a human vIL-2 cytokine for the treatment of human ovarian cancer
Cancer Gene Therapy, Published online: 10 November 2023; doi:10.1038/s41417-023-00674-3Boosting cytotoxicity of adoptive allogeneic NK cell therapy with an oncolytic adenovirus encoding a human vIL-2 cytokine for the treatment of human ovarian cancer (Source: Cancer Gene Therapy)
Source: Cancer Gene Therapy - November 10, 2023 Category: Cancer & Oncology Authors: D. C. A. Quixabeira S. Pakola E. Jirovec R. Havunen S. Basnet J. M. Santos T. V. Kudling J. H. A. Clubb L. Haybout V. Arias S. Gr önberg-Vähä-Koskela V. Cervera-Carrascon E. Kerkel ä A. Pasanen M. Anttila J. Tapper A. Kanerva A. Hemminki Source Type: research
MBD1 protects replication fork stability by recruiting PARP1 and controlling transcription-replication conflicts
Cancer Gene Therapy, Published online: 10 November 2023; doi:10.1038/s41417-023-00685-0MBD1 protects replication fork stability by recruiting PARP1 and controlling transcription-replication conflicts (Source: Cancer Gene Therapy)
Source: Cancer Gene Therapy - November 10, 2023 Category: Cancer & Oncology Authors: Guihui Yu Yundong Xiong Zhanzhan Xu Lei Zhang Xiao Albert Zhou Chen Nie Shiwei Li Weibin Wang Xiaoman Li Jiadong Wang Source Type: research
Identification of circATG9A as a novel biomarker for renal cell carcinoma
Cancer Gene Therapy, Published online: 09 November 2023; doi:10.1038/s41417-023-00684-1Identification of circATG9A as a novel biomarker for renal cell carcinoma (Source: Cancer Gene Therapy)
Source: Cancer Gene Therapy - November 9, 2023 Category: Cancer & Oncology Authors: Ye Shen Ruipeng Wu Zou Zhuo Ximeng Deng Weijian Li Changkun Liu Source Type: research
Antibody-mediated delivery of viral epitopes to redirect EBV-specific CD8+ T-cell immunity towards cancer cells
Cancer Gene Therapy, Published online: 09 November 2023; doi:10.1038/s41417-023-00681-4Antibody-mediated delivery of viral epitopes to redirect EBV-specific CD8+ T-cell immunity towards cancer cells (Source: Cancer Gene Therapy)
Source: Cancer Gene Therapy - November 9, 2023 Category: Cancer & Oncology Authors: Willemijn van der Wulp Dennis F. G. Remst Michel G. D. Kester Renate S. Hagedoorn Paul W. H. I. Parren Sander I. van Kasteren Janine Schuurman Rob C. Hoeben Maaike E. Ressing Boris Bleijlevens Mirjam H. M. Heemskerk Source Type: research
Tafazzin mediates tamoxifen resistance by regulating cellular phospholipid composition in ER-positive breast cancer
Cancer Gene Therapy, Published online: 07 November 2023; doi:10.1038/s41417-023-00683-2Tafazzin mediates tamoxifen resistance by regulating cellular phospholipid composition in ER-positive breast cancer (Source: Cancer Gene Therapy)
Source: Cancer Gene Therapy - November 7, 2023 Category: Cancer & Oncology Authors: Xuan Li Yuan Zhang Tengjiang Zhang Luyang Zhao Christopher G. Lin Haitian Hu Hanqiu Zheng Source Type: research
LAMC2 mitigates ER stress by enhancing ER-mitochondria interaction via binding to MYH9 and MYH10
Cancer Gene Therapy, Published online: 27 October 2023; doi:10.1038/s41417-023-00680-5LAMC2 mitigates ER stress by enhancing ER-mitochondria interaction via binding to MYH9 and MYH10 (Source: Cancer Gene Therapy)
Source: Cancer Gene Therapy - October 27, 2023 Category: Cancer & Oncology Authors: Dongdong Tong Jun Zhou Jing Zhou Xiaofei Wang Beibei Gao Xiaoyi Rui Liying Liu QiaoYi Chen Chen Huang Source Type: research
LncRNA CALML3-AS1 modulated by m6A modification induces BTNL9 methylation to drive non-small-cell lung cancer progression
Cancer Gene Therapy, Published online: 27 October 2023; doi:10.1038/s41417-023-00670-7LncRNA CALML3-AS1 modulated by m6A modification induces BTNL9 methylation to drive non-small-cell lung cancer progression (Source: Cancer Gene Therapy)
Source: Cancer Gene Therapy - October 27, 2023 Category: Cancer & Oncology Authors: Heng Zhang Shao-Qiang Wang Jie-Bo Zhu Li-Na Wang Hang Lin Lin-Feng Li Yuan-Da Cheng Chao-Jun Duan Chun-Fang Zhang Source Type: research
The effects of intracellular and exosomal ncRNAs on cancer progression
Cancer Gene Therapy, Published online: 26 October 2023; doi:10.1038/s41417-023-00679-yThe effects of intracellular and exosomal ncRNAs on cancer progression (Source: Cancer Gene Therapy)
Source: Cancer Gene Therapy - October 26, 2023 Category: Cancer & Oncology Authors: Yang-Hsiang Lin Source Type: research
GTF2E2 downregulated by miR-340-5p inhibits the malignant progression of glioblastoma
Cancer Gene Therapy, Published online: 16 October 2023; doi:10.1038/s41417-023-00676-1GTF2E2 downregulated by miR-340-5p inhibits the malignant progression of glioblastoma (Source: Cancer Gene Therapy)
Source: Cancer Gene Therapy - October 16, 2023 Category: Cancer & Oncology Authors: Xiaolong Qiao Yinan Chen Zixuan Wang Nan Peng Wanxiang Niu Shiqiang Hou Jiaying Wu Ying Ji Chaoshi Niu Chuandong Cheng Source Type: research
Retraction Note: Overexpressed transient receptor potential vanilloid 1 (TRPV1) in lung adenocarcinoma harbours a new opportunity for therapeutic targeting
Cancer Gene Therapy, Published online: 13 October 2023; doi:10.1038/s41417-023-00677-0Retraction Note: Overexpressed transient receptor potential vanilloid 1 (TRPV1) in lung adenocarcinoma harbours a new opportunity for therapeutic targeting (Source: Cancer Gene Therapy)
Source: Cancer Gene Therapy - October 13, 2023 Category: Cancer & Oncology Authors: Yichu Nie Fenglan Feng Wei Luo Andrew J. Sanders Yidi Zhang Jiaming Liang Cheng Chen Weineng Feng Weiquan Gu Weiping Liao Wei Wang Jinfeng Chen Lijian Zhang Wen G. Jiang Jin Li Source Type: research
Exploration of a screening model for intrahepatic cholangiocarcinoma patients prone to cuproptosis and mechanisms of the susceptibility of CD274-knockdown intrahepatic cholangiocarcinoma cells to cuproptosis
Cancer Gene Therapy, Published online: 12 October 2023; doi:10.1038/s41417-023-00673-4Exploration of a screening model for intrahepatic cholangiocarcinoma patients prone to cuproptosis and mechanisms of the susceptibility of CD274-knockdown intrahepatic cholangiocarcinoma cells to cuproptosis (Source: Cancer Gene Therapy)
Source: Cancer Gene Therapy - October 12, 2023 Category: Cancer & Oncology Authors: Zefeng Shen Jingwei Cai Liye Tao Junhao Zheng Zhengtao Ye Yang Liu Haoyu Pan Yali Wang Junjie Xu Xiao Liang Source Type: research
Reducing the risks of nuclear war—the role of health professionals
Cancer Gene Therapy, Published online: 12 October 2023; doi:10.1038/s41417-023-00671-6Reducing the risks of nuclear war—the role of health professionals (Source: Cancer Gene Therapy)
Source: Cancer Gene Therapy - October 12, 2023 Category: Cancer & Oncology Authors: Kamran Abbasi Parveen Ali Virginia Barbour Kirsten Bibbins-Domingo Marcel G. M. Olde Rikkert Richard Horton Robert Mash Carlos Monteiro Elena N. Naumova Eric J. Rubin Peush Sahni James Tumwine Paul Yonga Chris Zielinski Arun Mitra Tilman Ruff Andy Haines Source Type: research
Anti-leukemia effects of omipalisib in acute myeloid leukemia: inhibition of PI3K/AKT/mTOR signaling and suppression of mitochondrial biogenesis
Cancer Gene Therapy, Published online: 11 October 2023; doi:10.1038/s41417-023-00675-2Anti-leukemia effects of omipalisib in acute myeloid leukemia: inhibition of PI3K/AKT/mTOR signaling and suppression of mitochondrial biogenesis (Source: Cancer Gene Therapy)
Source: Cancer Gene Therapy - October 11, 2023 Category: Cancer & Oncology Authors: Chi-Yang Tseng Yu-Hsuan Fu Da-Liang Ou Jeng-Wei Lu Hsin-An Hou Liang-In Lin Source Type: research
Correction to: Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3
Cancer Gene Therapy, Published online: 03 October 2023; doi:10.1038/s41417-023-00672-5Correction to: Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3 (Source: Cancer Gene Therapy)
Source: Cancer Gene Therapy - October 3, 2023 Category: Cancer & Oncology Authors: R. Gan Y. Yang X. Yang L. Zhao J. Lu Q. H. Meng Source Type: research
Correction: α-Catenin acetylation is essential for its stability and blocks its tumor suppressor effects in breast cancer through Yap1
Cancer Gene Therapy, Published online: 22 September 2023; doi:10.1038/s41417-023-00668-1Correction: α-Catenin acetylation is essential for its stability and blocks its tumor suppressor effects in breast cancer through Yap1 (Source: Cancer Gene Therapy)
Source: Cancer Gene Therapy - September 22, 2023 Category: Cancer & Oncology Authors: Yuxi Yang Shujing Li Yulin Li Linlin Lv Dongman Ye Jie Kang Tao Yu Yaming Wang Huijian Wu Source Type: research
